Paul M Mckeigue

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4893355/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Flash monitor initiation is associated with improvements in HbA1c levels and DKA rates among people with type 1 diabetes in Scotland: a retrospective nationwide observational study. Diabetologia, 2022, 65, 159-172.	6.3	12
2	Vaccine efficacy against severe COVID-19 in relation to delta variant (B.1.617.2) and time since second dose in patients in Scotland (REACT-SCOT): a case-control study. Lancet Respiratory Medicine,the, 2022, 10, 566-572.	10.7	23
3	Risk of severe COVID-19 in patients with inflammatory rheumatic diseases treated with immunosuppressive therapy in Scotland. Scandinavian Journal of Rheumatology, 2022, , 1-6.	1.1	2
4	Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial. Nature Medicine, 2022, 28, 1256-1268.	30.7	105
5	Quantitative levels of serum <i>N</i> -glycans in type 1 diabetes and their association with kidney disease. Glycobiology, 2021, 31, 613-623.	2.5	6
6	Risks of and risk factors for COVID-19 disease in people with diabetes: a cohort study of the total population of Scotland. Lancet Diabetes and Endocrinology,the, 2021, 9, 82-93.	11.4	251
7	Relation of severe COVID-19 to polypharmacy and prescribing of psychotropic drugs: the REACT-SCOT case-control study. BMC Medicine, 2021, 19, 51.	5.5	41
8	The association of polypharmacy and high-risk drug classes with adverse health outcomes in the Scottish population with type 1 diabetes. Diabetologia, 2021, 64, 1309-1319.	6.3	5
9	Sharing a household with children and risk of COVID-19: a study of over 300 000 adults living in healthcare worker households in Scotland. Archives of Disease in Childhood, 2021, 106, 1212-1217.	1.9	36
10	Marked improvements in glycaemic outcomes following insulin pump therapy initiation in people with type 1 diabetes: a nationwide observational study in Scotland. Diabetologia, 2021, 64, 1320-1331.	6.3	19
11	Microvascular disease in diabetes and severe COVID-19 outcomes – Authors' reply. Lancet Diabetes and Endocrinology,the, 2021, 9, 201.	11.4	0
12	Relation of severe COVID-19 in Scotland to transmission-related factors and risk conditions eligible for shielding support: REACT-SCOT case-control study. BMC Medicine, 2021, 19, 149.	5.5	26
13	Development and validation of a cardiovascular risk prediction model in type 1 diabetes. Diabetologia, 2021, 64, 2001-2011.	6.3	22
14	Rising Rates and Widening Socioeconomic Disparities in Diabetic Ketoacidosis in Type 1 Diabetes in Scotland: A Nationwide Retrospective Cohort Observational Study. Diabetes Care, 2021, 44, 2010-2017.	8.6	8
15	Risk of hospital admission with covid-19 among teachers compared with healthcare workers and other adults of working age in Scotland, March 2020 to July 2021: population based case-control study. BMJ, The, 2021, 374, n2060.	6.0	23
16	Clinical Impact of Residual C-Peptide Secretion in Type 1 Diabetes on Glycemia and Microvascular Complications. Diabetes Care, 2021, 44, 390-398.	8.6	55
17	Association of cerebral venous thrombosis with recent COVID-19 vaccination: case-crossover study using ascertainment through neuroimaging in Scotland. BMC Infectious Diseases, 2021, 21, 1275.	2.9	13
18	Comparison of serum and urinary biomarker panels with albumin/creatinine ratio in the prediction of renal function decline in type 1 diabetes. Diabetologia, 2020, 63, 788-798.	6.3	31

PAUL M MCKEIGUE

#	Article	IF	CITATIONS
19	Predicting renal disease progression in a large contemporary cohort with type 1 diabetes mellitus. Diabetologia, 2020, 63, 636-647.	6.3	22
20	Rapid Epidemiological Analysis of Comorbidities and Treatments as risk factors for COVID-19 in Scotland (REACT-SCOT): A population-based case-control study. PLoS Medicine, 2020, 17, e1003374.	8.4	61
21	Investigation of genetically regulated gene expression and response to treatment in rheumatoid arthritis highlights an association between <i>IL18RAP</i> expression and treatment response. Annals of the Rheumatic Diseases, 2020, 79, 1446-1452.	0.9	13
22	Risk of hospital admission with coronavirus disease 2019 in healthcare workers and their households: nationwide linkage cohort study. BMJ, The, 2020, 371, m3582.	6.0	261
23	Biomarkers associated with early stages of kidney disease in adolescents with type 1 diabetes. Pediatric Diabetes, 2020, 21, 1322-1332.	2.9	9
24	Diabetic Neuropathy Is a Substantial Burden in People With Type 1 Diabetes and Is Strongly Associated With Socioeconomic Disadvantage: A Population-Representative Study From Scotland. Diabetes Care, 2020, 43, 734-742.	8.6	22
25	Time trends in deaths before age 50Âyears in people with type 1 diabetes: a nationwide analysis from Scotland 2004–2017. Diabetologia, 2020, 63, 1626-1636.	6.3	6
26	Prediction of colorectal cancer risk based on profiling with common genetic variants. International Journal of Cancer, 2020, 147, 3431-3437.	5.1	17
27	Prescribing Paradigm Shift? Applying the 2019 European Society of Cardiology–Led Guidelines on Diabetes, Prediabetes, and Cardiovascular Disease to Assess Eligibility for Sodium–Glucose Cotransporter 2 Inhibitors or Glucagon-Like Peptide 1 Receptor Agonists as First-Line Monotherapy (or) Tj ETQq1	1 %. 7843	14 ¹³ gBT /Ove
28	Expression quantitative trait loci-derived scores and white matter microstructure in UK Biobank: a novel approach to integrating genetics and neuroimaging. Translational Psychiatry, 2020, 10, 55.	4.8	8
29	Title is missing!. , 2020, 17, e1003374.		0
30	Title is missing!. , 2020, 17, e1003374.		0
31	Title is missing!. , 2020, 17, e1003374.		0
32	Title is missing!. , 2020, 17, e1003374.		0
33	Title is missing!. , 2020, 17, e1003374.		0
34	Quantifying performance of a diagnostic test as the expected information for discrimination: Relation to the <i>C</i> -statistic. Statistical Methods in Medical Research, 2019, 28, 1841-1851.	1.5	19
35	Genetically determined serum urate levels and cardiovascular and other diseases in UK Biobank cohort: A phenome-wide mendelian randomization study. PLoS Medicine, 2019, 16, e1002937.	8.4	81
36	Use of personalised risk-based screening schedules to optimise workload and sojourn time in screening programmes for diabetic retinopathy: A retrospective cohort study. PLoS Medicine, 2019, 16, e1002945.	8.4	12

PAUL M MCKEIGUE

#	Article	IF	CITATIONS
37	Persistent C-peptide secretion in Type 1 diabetes and its relationship to the genetic architecture of diabetes. BMC Medicine, 2019, 17, 165.	5.5	43
38	Phenome-wide Mendelian-randomization study of genetically determined vitamin D on multiple health outcomes using the UK Biobank study. International Journal of Epidemiology, 2019, 48, 1425-1434.	1.9	61
39	Biomarker panels associated with progression of renal disease in type 1 diabetes. Diabetologia, 2019, 62, 1616-1627.	6.3	41
40	Glycaemic control trends in people with type 1 diabetes in Scotland 2004–2016. Diabetologia, 2019, 62, 1375-1384.	6.3	45
41	Association of response to TNF inhibitors in rheumatoid arthritis with quantitative trait loci for <i>CD40</i> and CD39. Annals of the Rheumatic Diseases, 2019, 78, 1055-1061.	0.9	25
42	Validity of a two-component imaging-derived disease activity score for improved assessment of synovitis in early rheumatoid arthritis. Rheumatology, 2019, 58, 1400-1409.	1.9	39
43	The effect of dapagliflozin on glycaemic control and other cardiovascular disease risk factors in type 2 diabetes mellitus: a real-world observational study. Diabetologia, 2019, 62, 621-632.	6.3	33
44	Serum kidney injury molecule 1 and β2-microglobulin perform as well as larger biomarker panels for prediction of rapid decline in renal function in type 2 diabetes. Diabetologia, 2019, 62, 156-168.	6.3	50
45	Sample size requirements for learning to classify with high-dimensional biomarker panels. Statistical Methods in Medical Research, 2019, 28, 904-910.	1.5	9
46	MR-PheWAS: exploring the causal effect of SUA level on multiple disease outcomes by using genetic instruments in UK Biobank. Annals of the Rheumatic Diseases, 2018, 77, 1039-1047.	0.9	57
47	A Genome-Wide Association Study of Diabetic Kidney Disease in Subjects With Type 2 Diabetes. Diabetes, 2018, 67, 1414-1427.	0.6	136
48	N-Glycan Profile and Kidney Disease in Type 1 Diabetes. Diabetes Care, 2018, 41, 79-87.	8.6	75
49	Prediction of treatment response in rheumatoid arthritis patients using genomeâ€wide SNP data. Genetic Epidemiology, 2018, 42, 754-771.	1.3	15
50	Genome-wide association study of response to tumour necrosis factor inhibitor therapy in rheumatoid arthritis. Pharmacogenomics Journal, 2018, 18, 657-664.	2.0	41
51	GeneImp: Fast Imputation to Large Reference Panels Using Genotype Likelihoods from Ultralow Coverage Sequencing. Genetics, 2017, 206, 91-104.	2.9	38
52	Automated pathway and reaction prediction facilitates in silico identification of unknown metabolites in human cohort studies. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2017, 1071, 58-67.	2.3	16
53	Modelling cumulative exposure for inference about drug effects in observational studies. Pharmacoepidemiology and Drug Safety, 2017, 26, 1527-1533.	1.9	7
54	GWAS for male-pattern baldness identifies 71 susceptibility loci explaining 38% of the risk. Nature Communications, 2017, 8, 1584.	12.8	61

PAUL M MCKEIGUE

#	Article	IF	CITATIONS
55	The Genetic Landscape of Renal Complications in Type 1 Diabetes. Journal of the American Society of Nephrology: JASN, 2017, 28, 557-574.	6.1	101
56	Meta-analysis of genome-wide association studies of HDL cholesterol response to statins. Journal of Medical Genetics, 2016, 53, 835-845.	3.2	28
57	Biomarkers of rapid chronic kidney disease progression in type 2 diabetes. Kidney International, 2015, 88, 888-896.	5.2	124
58	Extending Admixture Mapping to Nuclear Pedigrees: Application to Sarcoidosis. Genetic Epidemiology, 2013, 37, 256-266.	1.3	6
59	Efficacy of COVID-19 vaccination in individuals designated as clinically extremely vulnerable in Scotland. F1000Research, 0, 10, 663.	1.6	2
60	Fitting joint models of longitudinal observations and time to event by sequential Bayesian updating. Statistical Methods in Medical Research, 0, , 096228022211042.	1.5	0